Abstract
The emergence of novel antithrombotic agents may have a dramatic impact on anticoagulation clinics and other providers of anticoagulation services. Of the novel agents currently in development, the oral direct thrombin inhibitor ximelagatran shows the most promise as an agent to improve the field of oral anticoagulation management because it is easier and more convenient to use than warfarin. Ximelagatran is currently being investigated for several indications, including prophylaxis of venous thromboembolism in patients undergoing orthopedic surgery, venous thrombosis treatment, stroke prevention in atrial fibrillation, and acute coronary syndromes. Anticoagulation clinics presently provide systematic, organized management of oral anticoagulation therapy (warfarin in the US) and provide better patient outcomes than usual medical care. The introduction of ximelagatran in patient management may dramatically alter the workload dynamics in anticoagulation clinics. Clinics that will survive the introduction of novel agents will most likely shift from a main focus of warfarin monitoring to thrombotic disease management and coordination of all antithrombotic therapy. Comprehensive Antithrombosis Centers (CAC) will most likely manage patients with thrombotic disorders treated with a range of anticoagulant therapies.
Similar content being viewed by others
References
Nutescu E, Racine E. Traditional versus modern anticoagulant strategies: Summary of the literature. Am J Health Syst Pharm 2002;59(20; Suppl 6):S7-S14.
Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. Chest 2001;119:22S-38S.
Berrettini M. Anticoagulation clinics: The Italian experience. Haematologica 1997;82(6):713-717.
Sam C, Speckman J, Moskowitz M, Ansell J. The Management of warfarin therapy by anticoagulation clinics: Results of a forum survey. Anticoagulation Forum Newsletter 2000;5(2):1-4.
Bongiorno R, Nutescu E. A national survey of anticoagulation clinics on the use of brand versus generic warfarin. Pharmacotherapy 1999;19(10):1204.
Errichetti AM, Holden A, Ansell J. Management of oral anticoagulant therapy: Experience with an anticoagulation clinic. Arch Intern Med 1984;144:1966-1968.
Charney R, Leddomado E, Rose DN, et al. Anticoagulation clinics and the monitoring of anticoagulant therapy. Int J Cardiol 1988;18:197-206.
Bussey HI, Rospond RM, Quandt CM, et al. The safety and effectiveness of long-term warfarin therapy in an anticoagulation clinic. Pharmacotherapy 1989;9:214-219.
Conte RR, Kehoe WA, Nielson N, et al. Nine-year experience with a pharmacist-managed anticoagulation clinic. Am J Hosp Pharm 1986;43:2460-2464.
Garabedian-Ruffalo SM, Gray DR, Sax MJ, et al. Retrospective evaluation of a pharmacist-managed warfarin anticoagulation clinic. Am J Hosp Pharm 1985;42:304-308.
Cortelazzo S, Finazzi G, Viero P, et al. Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic. Thromb Haemost 1993;69:316-320.
Wilt VM, Gums JG, Ahmed OI, et al. Pharmacy operated anticoagulation service: Improved outcomes in patients on warfarin. Pharmacotherapy 1995;15:732-779.
Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic and usual medical care: Anticoagulation control, patient outcomes, and health care costs. Arch Int Med 1998;158:1641-1647.
Gray DR, Garabedian-Ruffalo SM, Chretien SD. Cost justi-fication of a clinical pharmacist-managed anticoagulation clinic. Drug Intell Clin Pharm 1985;19:575-580.
Wahlander K, Lapidus L, Olsson CG, et al. Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. Thromb Res 2002;107:93-99.
Steinmetzer T, Hauptmann J, Sturzebecher J. Advances in the development of thrombin inhibitors. Expert Opin Investig Drugs 2001;10:845-864.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nutescu, E.A. The Future of Anticoagulation Clinics. J Thromb Thrombolysis 16, 61–63 (2003). https://doi.org/10.1023/B:THRO.0000014595.46367.89
Issue Date:
DOI: https://doi.org/10.1023/B:THRO.0000014595.46367.89